Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$3.36 ▼ -0.36
(-9.68%)
MKT CAP: $535.3M • VOL: 39.0K
52W L $3 52W H $45
ROARABLE / RQD
D- • 36/100
PIOTROSKI
5 / 9
NNNN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $8.6M | $8.2M | $6.7M |
| YoY Revenue Growth % | +5.6% | +21.9% | — |
| Gross Profit | $7.5M | $5.9M | — |
| Gross Margin % | 87.2% | 71.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $5.8M | $2.0M | $2.0M |
| Operating Margin % | 66.7% | 24.4% | 29.2% |
| Net Income (GAAP) | $6.4M | $2.4M | $2.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.7M | $2.1M | $898.4K |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$6.7M | $2.1M | $898.4K |
| FCF Margin % | -77.9% | 25.4% | 13.4% |
| Return on Invested Capital (ROIC %) | 20.4% | 29.0% | — |
| Cash & Short-Term Equivalents | $7.8M | $11.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $30.2M | $17.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NNNN.